.png)
SummaryGermany's GKV-Beitragssatzstabilisierungsgesetz, the Statutory Health Insurance Contribution Rate Stabilisation Act or BStabG for short, is a turning point for the pharmaceutical industry. Three new instruments are set to change, at the same time, how patent-protected medicines in Germany are priced, tendered and reimbursed. This article explains the three instruments, who they affect and what they mean for manufacturers, wholesale, pharmacies and health insurance funds, based on the official government bill. It is written for professionals, not patients.
The background is a structural funding crisis in the statutory health insurance. In 2024 the health insurance funds and the health fund recorded a combined deficit of almost 10 billion euro.2 Without countermeasures the funding gap of around 15 billion euro in 2027 would grow to up to 40 billion euro by 2030, and the total contribution rate would rise to as much as 19.3 percent.2 The act is intended to relieve the statutory health insurance (GKV) by around 16 billion euro in 2027.2
| Change | Who is affected | From when |
|---|---|---|
| Dynamic manufacturer discount | Manufacturers of patent-protected medicines | 1 Jan 2027 (static 3.5% at first, recalculated annually from 1 Jul 2027) |
| Rebate contracts for patent drugs (new section 130e) | Manufacturers, funds, pharmacies, physicians | Expected on the act entering into force |
| Tightened price moratorium | Generic and originator manufacturers | 1 Jan 2027 |
The existing general manufacturer discount of 7 percent (section 130a(1) SGB V) is to be supplemented by a dynamic component.2 The start is two-stage: from 1 January to 30 June 2027 a transitional static additional discount of 3.5 percent applies; from 1 July 2027, and annually thereafter, the discount is recalculated. The Federal Ministry of Health announces the value by 1 June each year, and it applies for twelve months.
Basis of the calculation: using data from the GKV umbrella association, the ministry compares expenditure growth in the patent market with the contributory revenue of the GKV. If expenditure rises faster than revenue, the discount rises. The height of the future discount therefore depends on factors no single manufacturer can influence, the expenditure growth of all patent-protected medicines in the market and the revenue trend of the entire GKV, so the pricing and volume decisions of other companies feed directly into a manufacturer's own discount.
The bill provides for a differentiated system of exemptions. Among others, reference-price medicines, biosimilars, vaccines and further groups expressly defined in the act are exempt, including certain supply-critical medicines and those with a qualified German nexus. The precise delineation follows from section 130a(1b) SGB V draft.2 In practice, flagging exposure in the IFA data is likely to be required, and manufacturers should already be checking the exemption criteria systematically for their portfolio.
The previous section 130e SGB V (combination discount) is abolished. In its place comes a fundamentally new rule: health insurance funds may, for the first time, sign rebate contracts for patent-protected active ingredients, and tender therapeutically comparable active ingredients against one another.2 In a pilot phase until 31 December 2030 this is possible for five defined substance groups:2
Assessing therapeutic comparability and forming the concrete tender groups lies with the health insurance funds, the group formation is done by the funds and their associations, not by the G-BA.2 Funds can select from the five pilot groups which active ingredients they define as equivalent and include in a tender. Contract physicians are generally to prescribe the rebated medicine of the respective contract group preferentially, while medically justified exceptions remain possible.2
Under the current procedural plan the rule could enter into force after the Bundesrat procedure in July 2026.3 Because designing the tenders requires substantial legal preparation, first procedures are realistically not to be expected before late 2026 or early 2027. An evaluation of the pilot phase is scheduled by 31 December 2030.2
The price moratorium has applied since 2010: the reference is the manufacturer selling price as of 1 August 2009, or the launch date for later introductions. Price increases beyond this base price must be repaid as an additional manufacturer discount, with an inflation adjustment possible on 1 July each year.
Until now the moratorium reference related to the same pharmaceutical company. Under the government bill the extended price moratorium is no longer to attach to the same company, but to medicines already on the market with the same active ingredient and a comparable dosage form, regardless of manufacturer.2 This could mean that early market entries after patent expiry have a stronger influence on later price references. Manufacturers planning to enter the market after a patent expiry should know the price already set in the market at that point and factor it into their launch strategy.
All three instruments hit at once: an additional, hard-to-calculate discount, price competition despite patent protection, and a tightened moratorium system. The immediate tasks differ by role.
Manufacturers and market-access teams need a portfolio analysis (which products fall under the dynamic discount, which are protected by exemptions, which PZNs sit in one of the five section 130e pilot groups), price scenarios for the combined discounts across the 2027 to 2030 horizon, and, for generic manufacturers, a launch strategy that accounts for the price already set at market entry. Which products are potentially affected can be narrowed and prioritised on the basis of IFA protection flags, ATC codes and price-history data; a final exposure analysis, especially for the dynamic-discount exemptions, additionally requires the manufacturer's own internal classification. Our overview of pharmaceutical pricing and market access in Germany sets out the underlying data.
Pharmaceutical wholesale faces demand shifting within the five substance groups: the product with the award is dispensed preferentially, the others lose volume. Two concrete risks follow, a shortage risk if a contract winner hits capacity limits, and an inventory-value risk if prices move through tender terms or the dynamic discount. Active inventory management and a real-time view of reported shortages become decisive, which is where a drug shortage database for Germany fits in.
Pharmacies face growing complexity in the dispensing decision. Alongside existing generic rebate contracts and the biosimilar substitution duty under section 40c, exclusive award contracts for patent-protected active ingredients under section 130e may be added, each requiring current price and master data to dispense and bill correctly.
Health insurance funds gain new savings options in the patent market through section 130e. Because assessing therapeutic comparability and forming the groups lies with the funds themselves,2 internal processes, legal reviews and contract frameworks have to be newly developed, drawing on G-BA benefit assessments and reimbursement amounts as the basis for the equivalence assessment in the tender design.
12 June 2026 (planned): first reading in the Bundestag, referral to the Health Committee.1 26 June 2026 (planned): second and third reading and adoption in the Bundestag.3 10 July 2026 (planned): second passage in the Bundesrat, followed by signing and promulgation.3 Autumn 2026: IFA and ABDA are expected to define new data fields; manufacturers adjust IFA notifications. 1 January 2027: the dynamic manufacturer discount (static 3.5% for the first half-year) and the tightened price moratorium enter into force; an additional vaccine discount (plus 7% for patent-protected vaccines without a determinable reference discount) also applies from 1 January 2027.2 1 June 2027 (and annually): announcement of the recalculated dynamic discount, effective 1 July.2 31 December 2030: end of the section 130e pilot phase, evaluation, and a possible extension to further patent medicines.2
With the BStabG the legislator intervenes, if adopted as planned, on three fronts in the patent market at once: dynamic discounts without planning certainty, price competition despite patent protection, and a tightened moratorium system. Every market participant now needs a reliable data basis to assess the impact on their portfolio or their purchasing. Which products in a portfolio are potentially affected can already be analysed today on the basis of IFA, price and AMNOG data. pharmazie.com keeps professionals current with IFA data, price history, an AMNOG database and a shortage overview in one platform, exclusively for healthcare professionals.
1 Deutscher Bundestag: Stabilisierung der Beitragssätze in der gesetzlichen Krankenversicherung, first reading (planned 12 June 2026, published 29 May 2026). bundestag.de
2 Bundesregierung: government bill GKV-Beitragssatzstabilisierungsgesetz (BStabG), Drucksache 21/6130, 26 May 2026 (advance version). dserver.bundestag.de
3 Bundesministerium für Gesundheit: GKV-Beitragssatzstabilisierungsgesetz, procedural status. bundesgesundheitsministerium.de
